What is BPC-150, and is it the same as BPC-157?

Readers meet the labels BPC-150 and BPC-157 side by side, and the obvious question is whether BPC-150 is the same thing. We found no published paper describing a compound called BPC-150 in the literature we reviewed (PubMed records on BPC-157). The peptide that scientists have studied is BPC-157. This article explains how the BPC-150 label relates to BPC-157, summarises what the literature reports about BPC-157, including the outcomes the studies measured, the adverse findings and how it differs from TB-500 and ipamorelin, and sets out why none of it can be carried over to a product sold as BPC-150. Listings (laboratory research only, 18+): BPC-157 capsules compared.

Key takeaways

• No paper we reviewed uses the name BPC-150. Most papers concern BPC-157 directly, a 15-amino-acid peptide with the sequence GEPPPGKPADDAGLV; the rest are broader reviews of several peptides that include BPC-157.
• Free Muscle's own listing describes its BPC-150 product as marketed as a variant of BPC-157. Nothing we reviewed verifies what such a product contains, so BPC-157 findings cannot be assigned to it.
• Most BPC-157 research is in cells and animals. Human reports are three small studies that reviews describe as uncontrolled pilots, all involving injections (a retrospective chart review of 17 patients, of whom 16 were reached; 12 patients; and 2 participants). A 2026 review puts the total at fewer than 30 subjects.
• Two registered trials were found, one recruiting (a randomised, placebo-controlled Phase 2 trial) and one not yet recruiting (a Phase 1 pilot). Neither has posted results.
• Reviews describe BPC-157 as investigational. Reviews raise concerns about product quality. The FDA and USADA statements cited here concern missing human safety and efficacy information.
• Results from injection or oral animal studies cannot be assumed to apply to an oral capsule.
• This review includes a table of the adverse findings, and the reported absences of them, from the main sources (BPC-157 side effects) and a comparison of BPC-157 with TB-500 and ipamorelin by mechanism, evidence base and anti-doping status (the comparison section). The only head-to-head study found is in rats; there is no human head-to-head trial in the sources.
• This is educational information, not medical advice and not legal advice.

What is BPC-150?

We found no published paper describing a compound called BPC-150 in the literature we reviewed (PubMed records on BPC-157). The "BPC" part stands for body protection compound, a name used for a peptide described as isolated from human gastric juice (Józwiak et al., 2025). BPC 157 is described as a 15-amino-acid partial sequence of body protection compound isolated from human gastric juice (Chang et al., 2011); its sequence is GEPPPGKPADDAGLV (Sikiric et al., 2006).

On the evidence we have, BPC-150 appears to be a seller's product name, not a name used in the literature. Free Muscle uses it for one of its own research listings (the BPC-150 research listing), and the product page says the item is marketed as a variant of BPC-157. A designation chosen by a seller is not the same thing as a compound with a published chemical identity, a safety file or a body of experiments behind it.

BPC-150 versus BPC-157 in plain terms

A peptide is a short chain of amino acids (Mendias and Awan, 2026). A different sequence or length is a different molecule, so a capsule sold as BPC-150 is either the BPC-157 sequence under another name or something no study describes. In both cases the published BPC-157 papers do not tell us about that specific capsule. Identity and purity are properties of a batch, not of a literature search; see the listings section for how Free Muscle handles batch certificates.

How researchers think BPC-157 works

All mechanism work described here was done on BPC-157, not BPC-150, and in cells or animals.

One group cultured rat tendon fibroblasts, the cells that produce tendon tissue. Pieces of tendon grown with BPC-157 sent out more cells than untreated pieces, and the cells survived better under oxidative stress. The peptide did not directly increase cell proliferation in that assay. Treated cells also migrated more, and the proteins FAK and paxillin, which help cells attach and move, became more phosphorylated. The authors proposed that activation of the FAK-paxillin pathway explains these changes (Chang et al., 2011).

A later paper examined blood vessel formation. In a chick membrane assay and in cultured endothelial cells, BPC-157 increased vessel density. In rats with hind-limb ischaemia, blood flow recovered faster after treatment. The paper linked this to increased expression of VEGFR2, a vascular growth receptor, and to activation of a signalling chain called VEGFR2-Akt-eNOS (Hsieh et al., 2017).

A 2025 scoping review describes overlapping pathways, notably VEGFR2 and nitric oxide synthesis via Akt-eNOS and ERK1/2 signalling, across animal models (McGuire et al., 2025). Reviewers are careful to say that the evidence is largely preclinical. A mechanism seen in a dish or in a rat is a hypothesis about people, not a demonstrated human effect.

Key studies at a glance

The table lists the main papers behind this article. Every row concerns BPC-157; none concerns BPC-150.

The evidence, study by study

No paper uses the name BPC-150. The studies below all concern BPC-157, and they are described as what happened to the named population in the named study. They are not predictions for any reader or for any product. The three human reports come first.

Human study 1: knee pain, retrospective chart review (Lee and Padgett, 2021)

This study took place at a clinic in Orlando, Florida (the Institute for Hormonal Balance). The investigators reviewed one year of charts from 2019 to 2020, covering 17 patients who had received an injection of BPC-157 into the knee joint, alone or combined with another peptide. Follow-up varied, with most injections having occurred six months to a year before the study. Sixteen patients were reached by telephone and asked to rate their pain before the injection, how long relief lasted and how much it helped. The authors state that no specific tools were used to measure function, quality of life, stiffness or daily activities.

Of the 12 patients who received BPC-157 alone, 11 (91.6%) reported significant improvement and one reported none. Of the four who received two peptides, 75% reported significant improvement. Overall, 14 of 16 patients (87.5%) reported relief (Lee and Padgett, 2021).

Limitations are substantial. The abstract states that the design was retrospective, that follow-up varied and that no specific tools measured function, quality of life, stiffness or daily activities. It describes no control group and no blinding, and the outcome was patients' own telephone ratings. The 2025 systematic review reports, for what appears to be a retrospective knee-injection study, that 7 of 12 patients reported relief lasting more than six months (Vasireddi et al., 2025). That is a different measure (duration of relief) from the "significant improvement" in the abstract, and the review's abstract does not name the paper, so the figures cannot be compared directly.

Human study 2: interstitial cystitis, uncontrolled pilot (Lee et al., 2024)

Twelve women aged 39 to 76 years, none of whom had responded to the approved drug pentosan polysulfate, took part at a private clinic. During cystoscopy, BPC-157 supplied by a compounding pharmacy was injected around the inflamed area of the bladder in a single procedure. The protocol quantity is given in the paper. Outcomes were measured with a Global Response Assessment questionnaire.

Ten of 12 women reported complete resolution of symptoms after one treatment. The other two rated their success at 80%. No one dropped out and no adverse events were reported (Lee et al., 2024).

Limitations: this was a single-arm pilot of 12 women, the abstract describes no control group and no blinding, the outcome was a patient questionnaire, and the sample was very small. The route, injection around the inflamed area of the bladder during cystoscopy, is clinical and is entirely different from swallowing a capsule.

Human study 3: intravenous safety pilot in two adults (Lee and Burgess, 2025)

This IRB-approved pilot involved a 58-year-old man and a 68-year-old woman, each of whom had received intravenous BPC-157 before the trial. Blood tests and vital signs were taken around each infusion across three days, and participants were asked about side effects. The infusion quantities are listed in the paper.

The authors reported no measurable effect on tested markers of the heart, liver, kidneys, thyroid or blood glucose, and no adverse effects. They also state that future studies are needed to confirm intravenous safety in humans (Lee and Burgess, 2025). With two participants, the study cannot rule out rarer or slower problems.

What the reviews conclude about the human data

A 2025 scoping review counted only three pilot studies of BPC-157 in humans, covering knee pain, interstitial cystitis and intravenous safety. It noted that no adverse effects were reported but that rigorous, large trials are lacking, and it advised treating BPC-157 as investigational (McGuire et al., 2025). A 2026 pharmaceutics review reached the same count and added that the clinical data come from fewer than 30 subjects across three uncontrolled pilots, none of which used standardised pharmaceutical preparations (Mateescu et al., 2026). Both papers are narrative or scoping reviews, so they summarise rather than formally grade the evidence.

Rat Achilles tendon study (Staresinic et al., 2003)

In this animal experiment, the Achilles tendon of rats was cut and the animals received BPC-157 by injection into the abdominal cavity or saline as a control. Recovery was assessed on days 1, 4, 7, 10 and 14. Compared with controls, treated rats showed greater load at failure, load of failure per area and Young's modulus of elasticity, higher values on the Achilles functional index and better microscopic and visible repair of the defect. In cultured tendon cells the peptide had no growth effect by itself but opposed a growth-inhibiting aldehyde (Staresinic et al., 2003).

Limitations: this is a rat study, and it shares authors (Seiwerth, Sikiric) with the 2010 ligament study below. The authors describe BPC-157 as in clinical trials for bowel disease; this is the group's own statement and we located no results. Separately, the United States Anti-Doping Agency (USADA) says studies investigating BPC-157 appear to have been cancelled or stopped without published conclusions.

Rat ligament study with three routes (Cerovecki et al., 2010)

Researchers cut the medial collateral ligament of the knee in rats and followed healing for up to 90 days. BPC-157 was given by injection into the abdominal cavity, as a thin layer of cream on the injury site, or by mouth through drinking water. The authors reported consistent functional, biomechanical, macroscopic and histological improvements across all three routes (Cerovecki et al., 2010).

The oral arm was rats drinking medicated water, no blood levels were reported in the abstract, and the paper shares authors (Seiwerth, Sikiric) with the tendon study above. It does not show what happens when a person swallows a capsule.

Mechanism studies (Chang et al., 2011; Hsieh et al., 2017)

These two papers are described in the mechanism section above. None of their authors appears on the two rat efficacy papers (Staresinic 2003; Cerovecki 2010). They used rat cells, human endothelial cells in culture, a chick membrane and rat limb ischaemia, not human participants.

Toxicology and pharmacokinetics (Xu et al., 2020; He et al., 2022)

Xu et al., 2020 and He et al., 2022 share authors, and He et al., 2022 describes the group as having established the synthesis process, so the two papers are not independent. The first tested BPC-157 in mice, rats, rabbits and dogs. Single-exposure studies showed no test-related effects. In repeated-exposure work, dogs tolerated the peptide with no abnormal findings except a decrease in creatinine at the higher of the dose levels the abstract compares (not seen at lower levels), which resolved after a two-week withdrawal. Local irritation was mild, and tests for genetic and embryo-fetal toxicity were negative (Xu et al., 2020).

The second paper measured pharmacokinetics in rats and beagle dogs after intravenous and intramuscular injection. The half-life of the intact peptide was under 30 minutes, the kinetics were linear, and intramuscular bioavailability was about 14 to 19% in rats and 45 to 51% in dogs. The peptide was broken down quickly into small fragments and single amino acids, and excretion was mainly through urine and bile (He et al., 2022). Neither paper reported oral data in its abstract, and both are animal studies.

Doping-control research (Cox et al., 2017; Tian et al., 2023)

Laboratories have developed urine tests for BPC-157. One group identified the peptide in confiscated vials and validated a urine method with a detection limit of 0.1 ng/mL (Cox et al., 2017). A later group using isotope-labelled peptide found nine metabolites in vitro (in two incubation models) and validated a method for BPC-157 and five main metabolites in human urine (Tian et al., 2023). These papers show that the compound can be detected; they say nothing about benefit.

Safety signals and what regulators and anti-doping bodies say

Reviews do not agree on how to read the safety record, and that disagreement is part of the picture. A 2025 literature and patent review says only a few side effects have been reported with BPC 157, while noting that it is not approved by the FDA or other global regulators because sufficient, comprehensive clinical studies in humans are missing (Józwiak et al., 2025). The 2025 systematic review found no clinical safety data and concluded that adverse effects remain possible because of unregulated manufacturing, contamination or unknown clinical safety (Vasireddi et al., 2025).

Other reviews are more cautious still. A 2026 Missouri Medicine review lists BPC-157 among unapproved peptides that lack established human safety profiles, and lists potential risks for such products as a group, including contamination, impurities, inaccurate dosing, pathological angiogenesis, carcinogenesis and cardiovascular stress (Moiz et al., 2026). A 2026 Sports Medicine review contrasts animal results with scarce human safety data and discusses the placebo effect and the way social media can amplify it (Mendias and Awan, 2026). A structured review in JBJS Reviews calls regenerative peptides investigational, with uncertain safety, product quality concerns and widespread anti-doping restrictions (Villegas Meza et al., 2026).

On the regulatory side, the US Food and Drug Administration lists BPC-157 on its page of compounding substances that may present significant safety risks, in the sub-list of nominated-but-withdrawn items. The page says the agency has identified no, or only limited, safety information for the proposed routes, so it cannot tell whether harm would result in humans. See the FDA compounding safety-risks page. This is a United States compounding statement rather than a UK one, and it does not say BPC-157 is banned.

The United States Anti-Doping Agency (USADA) states that no human clinical trials establish efficacy for BPC-157 for any diagnosis, that it is unknown whether there is a safe dose, and that a therapeutic use exemption is unlikely to be approved. USADA does not refer to the three small pilots described above; they are uncontrolled, so the accurate summary is that no controlled human trial has reported results, not that there are no human data.

Anecdotal accounts on forums or social media are not evidence of effect or of safety. Only published research, regulators and clinical guidance are cited here.

What the research does not tell us

Nothing was studied under the name BPC-150

The most important gap is the simplest. No paper uses the name BPC-150, and nothing we reviewed verifies that a capsule sold under that name contains BPC-157. Even if it does, the published findings describe specific preparations used in specific experiments.

The evidence hierarchy is low

Systematic reviewers classed the underlying literature as level IV and level V, and the 2026 JBJS Reviews paper rates its own recommendations as predominantly grade C. The reviews cited here call for well-designed, large-scale human trials (McGuire et al., 2025). The two registered trials below are the only ones found, and neither has posted results.

A ClinicalTrials.gov search on 2 October 2026 found two registered BPC-157 trials with relevant records. One is a randomised, double-blind, placebo-controlled Phase 2 trial in hamstring strain, recruiting (NCT07437547). The other is a Phase 1 pilot at the University of Arkansas in rotator cuff repair, not yet recruiting (NCT07803250). Both use injections, and neither has posted results.

Route and formulation: injection is not an oral capsule

Human reports describe injections into a knee, around the bladder and into a vein, and both registered trials use injections under the skin. The animal oral data we reviewed are rats given the peptide in drinking water (Cerovecki et al., 2010) and rats given it directly into the stomach (Sikiric et al., 2006); no oral bioavailability or blood-level measurement in humans was reported in the abstracts we reviewed. The 2026 pharmaceutics review calls human pharmacokinetics critically undercharacterised, notes unusual stability in gastric juice and says no pharmaceutical-grade formulation has been validated. It also highlights a disconnect between a half-life under 30 minutes and effects described as lasting hours to days (Mateescu et al., 2026). The review reports unusual stability in gastric juice; stability is not evidence of absorption. The cautious reading is that results from injection, cell culture or oral animal experiments cannot be assumed to apply to a capsule. The BPC-150 product page says it does not claim a capsule matches injection.

Other gaps

• No human reproductive, cancer-risk or long-term safety data were found in the abstracts we reviewed.
• The two rat efficacy studies we reviewed (Staresinic 2003; Cerovecki 2010) share authors (Seiwerth, Sikiric); we did not assess replication across the wider literature.
• The authors of the Staresinic 2003 and Sikiric 2006 papers describe BPC-157 as in clinical trials for bowel disease; this is the group's own statement and we located no results. Separately, USADA says studies investigating BPC-157 appear to have been cancelled or stopped without published conclusions.
• Product content was not independently checked by us. The identity and purity of any batch depend on its own analysis.

BPC-157 results: what the studies actually measured

A search for "BPC-157 results" usually expects one answer. The literature does not give one, because each study measured a different outcome in a different population with a different tool. Below, the published outcomes are grouped by what was measured, each with its own limits, and none of them was measured under the name BPC-150.

Patient-rated symptoms (humans, no comparison group)

The only human efficacy data are self-ratings. In the Orlando chart review, 11 of the 12 knee-pain patients who had the peptide alone rated their improvement as significant, and 14 of 16 overall reported relief, by telephone and with no comparison group (Lee and Padgett, 2021). In the bladder pilot, all 12 women scored 5 of 5 on the Global Response Assessment, 10 of them reporting full resolution and two rating their success at 80% (Lee et al., 2024). Because neither study had a comparison group, the share of these ratings that reflects placebo response or the natural course of the condition cannot be separated out; a 2026 review discusses the placebo effect as a mediator of peptide efficacy (Mendias and Awan, 2026).

Blood markers (humans, two participants)

In the intravenous pilot, markers of the heart, liver, kidneys, thyroid and blood glucose did not change measurably over three days in one man and one woman (Lee and Burgess, 2025). That is a tolerability observation in two people, not an efficacy result.

Tissue strength and function (rats)

Mechanical and functional outcomes come from rodents. After Achilles tendon transection, treated rats had a higher load at failure, higher load per area and a higher Young's modulus than saline controls, together with higher Achilles functional index values and a smaller defect on inspection (Staresinic et al., 2003). After ligament transection, functional, biomechanical, macroscopic and histological measures improved over 90 days by all three routes tested (Cerovecki et al., 2010). In a 2026 exploratory study of 32 rats after Achilles repair, maximum load to failure was higher in the BPC-157 group than in controls at four weeks but did not reach statistical significance, and the group's histological scores were numerically lower without reaching significance for total scores (Biçer et al., 2026).

Blood vessels and cell behaviour (cells, chick membrane, rats)

Vessel density increased in the chick membrane and tube-formation assays and blood flow recovered faster in ischaemic rat hind limbs (Hsieh et al., 2017); explant outgrowth, survival under peroxide stress and migration increased in rat tendon fibroblasts, without a direct effect on proliferation (Chang et al., 2011). They come from cells, a chick membrane and rats, not from people (see also the mechanism section).

The limits that travel with every result above

The human figures come from fewer than 30 people in three uncontrolled pilots that used non-standard preparations (Mateescu et al., 2026). The systematic review found no clinical safety data and graded the literature level IV and V (Vasireddi et al., 2025). A 2026 scoping review of six marketed peptides, BPC-157 among them, found that human studies were limited to a handful of investigations, most lacking robust controls, and concluded that the claimed effects remain unsubstantiated by current human trials (Tewari et al., 2026). Every human report used an injection or an infusion; none measured an oral capsule, so none of these results can be assumed to apply to one.

BPC-157 side effects reported in the research

A search for "BPC-157 side effects" deserves a complete answer rather than a reassuring one. The table lists the adverse findings, and the reported absences of them, from the main sources behind this article, together with the population in which each was observed. An absence of reported events in a very small uncontrolled study is not a demonstration of safety, and each row should be read alongside the class-level warnings further down the table. Nothing in the table concerns a product sold as BPC-150.

What pilots and case series can and cannot show

A single-arm series of 12 patients, or a report on two volunteers, can record obvious reactions that happened to those people during the observation window. It cannot detect uncommon reactions, reactions that appear months later, or changes that only a laboratory panel over time would reveal, and without a comparison group it cannot say whether an event that did occur was caused by the peptide. The knee study illustrates the problem from the other side: its telephone survey asked about pain relief, and the abstract reports no adverse-event question, so its silence on harms tells us little (Lee and Padgett, 2021). The reviews cited above name unregulated manufacturing, contamination, impurities and inaccurate dosing as concerns for products outside a regulated supply chain (Vasireddi et al., 2025; Moiz et al., 2026), so even a reported event or a reported absence of events in a study cannot be assumed to describe any particular product.

The gaps are therefore the same ones listed earlier: no human reproductive, cancer-risk or long-term data in the abstracts reviewed, no oral human data at all, and no controlled trial of any kind with published results. The pathological angiogenesis concern raised at class level sits uneasily beside the pro-angiogenic mechanism described in the cell and rat work above; the sources do not resolve that tension, and we do not either.

BPC-157 vs TB-500 vs ipamorelin: how they differ

The three names are often searched together, but they belong to two different pharmacological groups. A 2026 structured review places BPC-157 and thymosin derivatives among "regenerative peptides" and ipamorelin among growth hormone axis secretagogues, and describes both groups as investigational with uncertain safety profiles, product quality concerns and widespread anti-doping restrictions (Villegas Meza et al., 2026). The table compares them on what the sources actually show. It does not rank them, and it cannot: no human trial in the sources has compared any two of them.

The single head-to-head experiment in the sources is in rats. Thirty-two male rats had a standardised Achilles tendon transection and repair and were randomised to four groups of eight: control, BPC-157, TB-500 and the combination. At four weeks, maximum load to failure was higher than control in both single-agent groups, reaching statistical significance only in the TB-500 group; total Bonar scores were significantly lower in the TB-500 group and total Movin scores significantly lower in the TB-500 and combination groups; and the combination gave no additional effect over either agent alone (Biçer et al., 2026). The authors call the study exploratory and ask for longer follow-up, and one rat experiment at one time point does not rank the two peptides. The protocol quantities are given in the paper.

Ipamorelin is the odd one out. It is classed by Villegas Meza et al., 2026 as a growth hormone axis secretagogue rather than a regenerative peptide, and it is the only one of the three with a completed randomised, placebo-controlled trial with published results in the sources for this article: a Phase 2 trial in 117 adults after bowel resection (postoperative ileus) in which ipamorelin did not differ significantly from placebo on the key or secondary efficacy analyses (Beck et al., 2014). The 2026 scoping review that covered all three names, with MK-677, CJC-1295 and GHK-Cu, found that 67% of the publications identified used animal models and that the human data were heterogeneous, and it did not recommend any of the six as a replacement for or addition to standard orthopaedic care (Tewari et al., 2026). For the research background on each comparator, see our separate articles on TB-500 and thymosin beta-4 and on ipamorelin, and the research peptides collection for the listings themselves. As with BPC-150, every listing is sold for laboratory research use only and nothing in the comparison is advice about any of them.

Legal and anti-doping status in brief

This is general information, not legal advice. Everything below comes from sources we verified, and we have found no UK regulator page that names BPC-157 or BPC-150, so no UK authority statement about either is attributed here.

UK medicines law

Under the Human Medicines Regulations 2012, a medicinal product includes any substance that may be used by or administered to human beings with a view to restoring, correcting or modifying a physiological function through a pharmacological, immunological or metabolic action (regulation 2). The same regulations provide that a person may not sell or supply, or offer to sell or supply, an unauthorised medicinal product (regulation 46). Products with such effects can fall within the definition. We are not stating that BPC-150 or BPC-157 has been classified as a medicine by any UK authority. Free Muscle sells its research compounds for laboratory research use only; they are not medicines or food supplements and not for human consumption.

Government guidance on advertising medicines also sets limits on how outcomes may be described. Whether it applies to a particular product is a legal question this article does not settle.

Anti-doping

USADA states that BPC-157 is prohibited under the S0 Non-Approved Substances category of the World Anti-Doping Agency (WADA) Prohibited List. A 2025 review says it was temporarily banned in 2022 and that it is not currently listed, which conflicts with USADA's page (Józwiak et al., 2025). We could not read the Prohibited List text directly, so this status should be checked against the current list published by WADA or your national anti-doping organisation. Clinicians writing in sports medicine journals advise counselling competitive athletes about anti-doping rules (Vasireddi et al., 2025) and about uncertain efficacy, product quality, safety risks and anti-doping implications (Villegas Meza et al., 2026).

Full breakdown with sources: Is BPC-157 legal in the UK?

About the Free Muscle BPC-150 listings

Free Muscle sells research compounds and gym apparel online at freemuscle.co.uk.

• Product: BPC-150 capsules (research listing). The product page names the item BPC-150 and describes it as marketed as a variant of BPC-157. This article does not establish whether it is or is not the literature peptide, and no paper uses the name BPC-150.
• Research compounds sold by Free Muscle are supplied for laboratory research use only and are not for human consumption. They are not authorised as medicines by the MHRA, EMA or FDA, are not food supplements, and are sold only to adults aged 18 or over. Nothing on this page is medical or dosing advice.
• Every batch of research compounds is assayed for identity and purity by Janoshik Analytical, an independent laboratory. The Certificate of Analysis for a batch is sent on request: email the batch number printed on the label with the product name. Details are on the laboratory testing page, and our guides explain how to read a certificate of analysis and what Janoshik Analytical is.
• Delivery and returns: see the shipping information and returns guarantee pages.

For wider background, read our overview of what the BPC-157 research shows and our explainer on whether oral peptides work.

Frequently asked questions

Is BPC-150 the same as BPC-157?

Not on the published record. BPC-157 is a defined 15-amino-acid peptide with a published research literature. BPC-150 is a designation used by Free Muscle, described on its product page as marketed as a variant of BPC-157, and no study uses that name.

What does BPC stand for?

It stands for body protection compound, the name used for a peptide described as isolated from human gastric juice. BPC 157 is described as a 15-amino-acid partial sequence of it (Chang et al., 2011).

Is there any research on BPC-150?

We found none. Every paper we reviewed concerns BPC-157, several of them as one peptide among many in broader reviews, and no paper uses the name BPC-150.

Have there been human trials of BPC-157?

There are three small human studies, which reviews describe as uncontrolled pilots, covering knee pain, interstitial cystitis and intravenous safety, plus two registered trials without results. The 2026 pharmaceutics review states there is no completed Phase II trial, and the 2025 scoping review says rigorous large-scale trials are lacking.

Does BPC-157 research apply to capsules?

That has not been established. Human reports involve injections, and the oral animal data we reviewed are from rats (drinking water or direct instillation into the stomach). Reviewers describe human pharmacokinetics as poorly characterised.

Is BPC-157 banned in sport?

USADA states it is prohibited under category S0 of the WADA list, while one 2025 review says it was only temporarily banned in 2022. Check the current WADA list directly.

Is BPC-157 legal in the UK?

The Human Medicines Regulations 2012 say a medicinal product includes any substance that may be used by or administered to human beings with a view to restoring, correcting or modifying a physiological function by a pharmacological, immunological or metabolic action (regulation 2), and that a person may not sell or supply an unauthorised medicinal product (regulation 46); products with such effects can fall within that definition. We found no UK regulator statement naming BPC-157. Our companion article on the BPC-157 UK legal position and quality guide goes through the legislation and the quality documents in more detail. This is general information, not legal advice.

What side effects has BPC-157 research reported?

The human reports are too small to say. The 12-woman bladder pilot and the two-person intravenous pilot reported no adverse events (Lee et al., 2024; Lee and Burgess, 2025), and animal toxicology found no serious toxicity apart from a creatinine decrease in dogs that resolved (Xu et al., 2020). The 2025 systematic review found no clinical safety data (Vasireddi et al., 2025), and a 2026 review says unapproved peptides including BPC-157 lack established human safety profiles and names contamination, impurities, inaccurate dosing, pathological angiogenesis, carcinogenesis and cardiovascular stress as potential risks for such products as a group (Moiz et al., 2026). The full list is in the side-effects table above.

What results have BPC-157 studies measured?

In people, only self-rated symptoms and, in two volunteers, blood markers: 11 of 12 knee-pain patients and 10 of 12 bladder-pain patients rated themselves improved or resolved in uncontrolled series (Lee and Padgett, 2021; Lee et al., 2024). In rats, tendon (Staresinic et al., 2003) and knee-ligament (Cerovecki et al., 2010) strength, function and histology improved against controls. No controlled human trial has published results, so none of these figures is a prediction for anyone.

BPC-157 vs TB-500: what is the difference?

BPC-157 is a 15-amino-acid gastric peptide; TB-500 is a product in which a seven-amino-acid acetylated fragment of thymosin beta-4 was identified (Esposito et al., 2012). The only head-to-head study is a 32-rat Achilles repair experiment in which both agents were associated with improved histology and only TB-500 reached significance on load to failure at four weeks (Biçer et al., 2026). No human comparison appears in the sources, no controlled human trial of BPC-157 has published results, and the sources contain no human trial of the TB-500 fragment. One rat experiment at one time point does not show that either peptide is superior. See the comparison section and our TB-500 article.

BPC-157 oral vs injection: what do the studies cover?

All three human reports and both registered trials used injections or infusions. Oral data are from rats drinking treated water or receiving the peptide directly into the stomach (Cerovecki et al., 2010; Sikiric et al., 2006), and the 2026 pharmaceutics review says human pharmacokinetics are critically undercharacterised and no pharmaceutical-grade formulation has been validated (Mateescu et al., 2026). Results from injection, cell culture or animal experiments cannot be assumed to apply to an oral capsule.

What does BPC-157 do, according to the research?

In rat tendon cells it increased outgrowth, survival under peroxide stress and migration, which the authors considered likely to be mediated by FAK-paxillin activation (Chang et al., 2011); in a chick membrane assay, cultured endothelial cells and rats with hind-limb ischaemia it increased vessel density or blood-flow recovery, which the authors associated with VEGFR2 expression and VEGFR2-Akt-eNOS signalling (Hsieh et al., 2017). These are findings in cells and animals, not in people. In humans, the three uncontrolled pilots recorded patient-rated improvement and no measurable change in blood markers. McGuire et al. say well-designed human trials are needed and that BPC-157 should be considered investigational (McGuire et al., 2025).

Does this article give doses or instructions for BPC-157?

No. This article gives no doses, schedules or protocols for any compound. The protocol quantities used in each experiment are in the linked papers and describe what was given to rats, dogs or patients in those studies, not guidance for anyone. The BPC-150 listing is sold for laboratory research use only, to customers aged 18 or over, and is not for human consumption. Neither the product page nor this article gives quantities, schedules or protocols.

Does BPC-157 show up in anti-doping tests?

Laboratories have validated urine methods for it. One group identified BPC-157 in confiscated vials and validated a urine method with a detection limit of 0.1 ng/mL (Cox et al., 2017), and a later group validated a method for the peptide and five main metabolites in human urine (Tian et al., 2023). USADA states the compound is prohibited under S0; anyone subject to testing should check the current list at WADA or UK Anti-Doping.

How can the quality of a research peptide be judged?

Independent laboratory analysis of the specific batch is the relevant evidence, together with a Certificate of Analysis you can match to the batch number on the label. Free Muscle publishes guidance on reading these certificates. Reviews cited here warn that unregulated manufacturing and contamination are real concerns for products outside regulated supply chains.

Related reading

• Short overview: BPC-157 UK 2026: What the Research Actually Shows
• Route comparison: BPC-157 capsules vs injection: what the studies actually used

Sources

1. Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021;27(4):8-13. PMID 34324435
2. Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med. 2024;30(10):12-17. PMID 39325560
3. Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025;31(5):20-24. PMID 40131143
4. Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025;21(4):485-495. doi:10.1177/15563316251355551. PMID 40756949
5. McGuire FP, Martinez R, Lenz A, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025;18(12):611-619. doi:10.1007/s12178-025-09990-7. PMID 40789979
6. Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and Possible Medical Application of the BPC 157 Peptide: Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2). doi:10.3390/ph18020185. PMID 40005999
7. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026;56(8):1921-1935. doi:10.1007/s40279-026-02437-0. PMID 41966639
8. Mateescu DM, Gavrilescu DM, Constantinescu FE, et al. BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. Pharmaceutics. 2026;18(5). doi:10.3390/pharmaceutics18050625. PMID 42198317
9. Villegas Meza AD, Nocek M, Mitchell BC, et al. Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications. JBJS Rev. 2026;14(5). doi:10.2106/JBJS.RVW.26.00027. PMID 42160466
10. Moiz A, O'Keefe EL, O'Keefe JH. Dangers of Injectable Peptides and Other Unregulated "Biohacking" Drugs. Mo Med. 2026;123(4):337-343. PMID 42757290
11. Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. doi:10.1016/S0736-0266(03)00110-4. PMID 14554208
12. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985). 2011;110(3):774-780. doi:10.1152/japplphysiol.00945.2010. PMID 21030672
13. Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. doi:10.1007/s00109-016-1488-y. PMID 27847966
14. Cerovecki T, Bojanic I, Brcic L, et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. J Orthop Res. 2010;28(9):1155-1161. doi:10.1002/jor.21107. PMID 20225319
15. Xu C, Sun L, Ren F, et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regul Toxicol Pharmacol. 2020;114:104665. doi:10.1016/j.yrtph.2020.104665. PMID 32334036
16. He L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1026182. doi:10.3389/fphar.2022.1026182. PMID 36588717
17. Cox HD, Miller GD, Eichner D. Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H. Drug Test Anal. 2017;9(10):1490-1498. doi:10.1002/dta.2152. PMID 28035768
18. Tian T, Jing J, Li Y, et al. Stable Isotope Labeling-Based Nontargeted Strategy for Characterization of the In Vitro Metabolic Profile of a Novel Doping BPC-157 in Doping Control by UHPLC-HRMS. Molecules. 2023;28(21). doi:10.3390/molecules28217345. PMID 37959764
19. Sikiric P, Seiwerth S, Brcic L, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular response. Inflammopharmacology. 2006;14(5-6):214-221. doi:10.1007/s10787-006-1531-7. PMID 17186181
20. Biçer O, Adanir O, Güleryüz Y, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37(3):822-837. doi:10.52312/jdrs.2026.2951. PMID 42542926
21. Tewari K, Liu TP, Im C, et al. Peptide Supplements and Their Therapeutic Applications in Sports Medicine. Am J Sports Med. 2026. doi:10.1177/03635465261464420. PMID 42578445
22. Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-738. doi:10.1002/dta.1402. PMID 22962027
23. Ho EN, Kwok WH, Lau MY, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012;1265:57-69. doi:10.1016/j.chroma.2012.09.043. PMID 23084823
24. Rahaman KA, et al. Detection and quantification of the metabolite Ac-Tβ1-14 in in vitro experiments and urine of rats treated with Ac-Tβ4: A potential biomarker of Ac-Tβ4 for doping tests. Drug Test Anal. 2023;15(11-12):1454-1467. doi:10.1002/dta.3552. PMID 37515313
25. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. doi:10.1530/eje.0.1390552. PMID 9849822
26. Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412-1416. doi:10.1023/a:1018955126402. PMID 10496658
27. Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29(12):1527-1534. doi:10.1007/s00384-014-2030-8. PMID 25331030
28. Semenistaya E, Zvereva I, Thomas A, et al. Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin. Drug Test Anal. 2015;7(10):919-925. doi:10.1002/dta.1787. PMID 25869809
29. Human Medicines Regulations 2012, regulations 2 and 46 (legislation.gov.uk).
30. US Food and Drug Administration. Certain ... Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 22 April 2026).
31. United States Anti-Doping Agency (USADA). Spirit of Sport: BPC-157 peptide prohibited (accessed 2 October 2026).
32. ClinicalTrials.gov records NCT07437547 and NCT07803250, queried 2 October 2026.